Rugo HS - Search Results

1

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.

Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J; I-SPY2 Investigators; Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ. Wolf DM, et al. Among authors: rugo hs. Cancer Cell. 2022 Jun 13;40(6):609-623.e6. doi: 10.1016/j.ccell.2022.05.005. Epub 2022 May 26. Cancer Cell. 2022. PMID: 35623341 Free PMC article. Clinical Trial.

2

High-dose chemotherapy (CTM) for breast cancer.

Damon LE, Wolf JL, Rugo HS, Gold E, Zander AR, Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, Linker CA. Damon LE, et al. Among authors: rugo hs. Bone Marrow Transplant. 2000 Aug;26(3):257-68. doi: 10.1038/sj.bmt.1702481. Bone Marrow Transplant. 2000. PMID: 10967563 Clinical Trial.

3

Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation.

Lang JE, Esserman LJ, Ewing CA, Rugo HS, Lane KT, Leong SP, Hwang ES. Lang JE, et al. Among authors: rugo hs. J Am Coll Surg. 2004 Dec;199(6):856-62. doi: 10.1016/j.jamcollsurg.2004.08.023. J Am Coll Surg. 2004. PMID: 15555967

4

MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. Partridge SC, et al. Among authors: rugo hs. AJR Am J Roentgenol. 2005 Jun;184(6):1774-81. doi: 10.2214/ajr.184.6.01841774. AJR Am J Roentgenol. 2005. PMID: 15908529

5

Hormonal therapy for advanced breast cancer.

Rugo HS. Rugo HS. Hematol Oncol Clin North Am. 2007 Apr;21(2):273-91. doi: 10.1016/j.hoc.2007.03.007. Hematol Oncol Clin North Am. 2007. PMID: 17512449 Review.

6

Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival.

Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS. Melisko ME, et al. Among authors: rugo hs. J Neurooncol. 2008 Jul;88(3):359-65. doi: 10.1007/s11060-008-9578-5. Epub 2008 Apr 9. J Neurooncol. 2008. PMID: 18398574

7

Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates.

Belkora J, Rugo HS, Moore DH, Hutton D, Esserman L. Belkora J, et al. Among authors: rugo hs. Lancet Oncol. 2008 Jul;9(7):602-3. doi: 10.1016/S1470-2045(08)70158-X. Lancet Oncol. 2008. PMID: 18598923 No abstract available.

8

Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.

Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman LJ. Belkora JK, et al. Among authors: rugo hs. BMC Cancer. 2009 Apr 28;9:127. doi: 10.1186/1471-2407-9-127. BMC Cancer. 2009. PMID: 19400938 Free PMC article.

9

Triple-negative breast cancer: role of antiangiogenic agents.

Greenberg S, Rugo HS. Greenberg S, et al. Among authors: rugo hs. Cancer J. 2010 Jan-Feb;16(1):33-8. doi: 10.1097/PPO.0b013e3181d38514. Cancer J. 2010. PMID: 20164688 Review.

10

The cardiac safety of trastuzumab in the treatment of breast cancer.

Chien AJ, Rugo HS. Chien AJ, et al. Among authors: rugo hs. Expert Opin Drug Saf. 2010 Mar;9(2):335-46. doi: 10.1517/14740331003627441. Expert Opin Drug Saf. 2010. PMID: 20175700 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

497 results

Search Page